.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,444,813

« Back to Dashboard

Details for Patent: 6,444,813

Title: Linezolid-crystal form II
Abstract:The invention is a process to produce a compound, linezolid ##STR1## which is useful as an antibacterial agent.
Inventor(s): Bergren; Michael S. (Portage, MI)
Assignee: Pharmacia & Upjohn Company (Kalamazoo, MI)
Filing Date:Jan 29, 2001
Application Number:09/772,239
Claims:1. A process to prepare (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide, crystal "Form II" which comprises: (1) producing (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide in greater than 98% enantiomeric purity, (2) mixing the greater than 98% enantiomerically pure (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide in a solvent or mixture of solvents at a temperature below a temperature of about 80.degree. and (3) separating the (S)-N-[[3-3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]ac etamide crystal "Form II" from the solvent(s).

2. A process according to claim 1 where the enantiomeric purity is greater than 99%.

3. A process according to claim 2 where the enantiomeric purity is greater than 99.5%.

4. A process according to claim 1 where the solvent is selected from the group consisting of compounds of the formula: water, acetonitrile, chloroform, methylene chloride, toluene, R.sub.1 --OH where R.sub.1 is C.sub.1 -C.sub.6 alkyl, R.sub.1 --CO--R.sub.2 where R.sub.2 is C.sub.1 -C.sub.6 alkyl or phenyl substituted with 1 thru 3 R.sub.1 where R.sub.1 is as defined above, and where R.sub.1 is as defined above, R.sub.1 --CO--O--R.sub.2 where R.sub.1 is C.sub.1 -C.sub.6 alkyl and R.sub.1 is as defined above, R.sub.1 --O--R.sub.2 where R.sub.1 is C.sub.1 -C.sub.6 alkyl and R.sub.1 is as defined above.

5. A process according to claim 4 where the solvent is selected from the group consisting of water, ethyl acetate, methanol, ethanol, propanol, i-propanol, butanol, acetonitrile, acetone, methyl ethyl ketone, chloroform, methylene chloride, toluene, xylene, diethyl ether, or methyl-t-butyl ether.

6. A process according to claim 4 where the solvent is selected from the group consisting of ethyl acetate, acetone, acetonitrile, propanol, or isopropanol.

7. A process according to claim 4 where the solvent is ethyl acetate.

8. A process according to claim 1 where the (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide is mixed for at least 10 min in the solvent or mixture of solvents.

9. A process according to claim 8 where the (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide is mixed for at least 20 min in the solvent or mixture of solvents.

10. A process according to claim 8 where the linezolid is mixed for at least 30 min in the solvent or mixture of solvents.

11. A process according to claim 1 where the temperature is less than about 75.degree..

12. A process according to claim 8 where the temperature is from about 45.degree. to about 60.degree..

13. A process according to claim 1 where the (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide is isolated as a solid before mixing with a solvent or mixture of solvents.

14. A process according to claim 1 where the (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide is kept in solution
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc